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Most strikingly, the frequencies of resistance of Staphy-
ococcus aureus isolates to methicillin—–MRSA (84.1% vs
6.8%), Klebsiella pneumoniae to ceftazidime or cef-
riaxone (76.1% vs 27.1%), Acinetobacter baumannii to
mipenem (46.3% vs 29.2%), and Pseudomonas aeruginosa
o piperacilline (78.0% vs 20.2%) were also far higher in
he consortium’s ICUs, and the crude unadjusted excess
ortalities of device-related infections ranged from 23.6%
CVC-associated BSI) to 29.3% (VAP).
oi:10.1016/j.ijid.2010.02.1506
easonal ﬂu vaccines: Current status and future
irections (Invited Presentation)
1.001
nﬂuenza vaccination: Where do we stand?
.E. Fiore
National Center for Infectious Diseases, CDC, Atlanta, GA,
SA
In the United States, inﬂuenza causes an average of
6,000 deaths and 226,000 hospitalizations yearly. Rates of
nfection are highest among children. Rates of serious ill-
ess and death are highest among persons aged ‘‘65 years,
hildren aged <2 years, and persons of any age with medical
onditions that place them at higher risk for complications
rom inﬂuenza.
Annual inﬂuenza vaccination is the most effective
ethod for preventing inﬂuenza virus infection and its
omplications. Inﬂuenza viruses undergo frequent antigenic
hange (antigenic drift); patients need an annual vacci-
ation against the inﬂuenza viruses that are predicted on
he basis of viral surveillance data. Trivalent inactivated
nﬂuenza vaccine (TIV) can be used for any person aged
‘6 months, including those with high-risk conditions. Live,
ttenuated inﬂuenza vaccine (LAIV) may be used for healthy,
onpregnant persons aged 2—49 years.
The 2009 novel inﬂuenza A (H1N1) pandemic required
separate monovalent vaccine to be rapidly developed,
ith different vaccination recommendations from those for
easonal vaccines. The initially limited supply of vaccine
equired that early vaccination efforts target children and
oung adults, adults <65 years old with chronic medical
onditions, pregnant women, and healthcare personnel. By
anuary 2010, monovalent vaccine supply had increased suf-
ciently to allow all persons who wanted vaccination to
eceive it.
Vaccination coverage has remained low in most groups
or a variety of reasons, including the need for annual revac-
ination, the complexity of vaccination recommendations,
nd a lack of knowledge among patients and healthcare
roviders. In recent years, simpler age-based recommen-
ations have been added for persons 50-64 years old, and
hildren ages 6 months through 18 years, and in 2009, >85%
f the US population had an indication for annual vacci-
ation. As more manufacturers have entered the market,
easonal vaccine supply has met demand. A universal vac-
ine recommendation for all persons aged 6 months or older
s feasible and has been proposed as a way to increase vac-
ine coverage in all age groups.
o
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Current inﬂuenza vaccines are safe in all age and risk
roups and quite effective in healthy children and younger
dults. Lower effectiveness among seniors and persons
ith chronic medical conditions, and lower immunogenicity
requiring 2 doses) among previously unvaccinated infants
nd children highlight unmet challenges. More effective vac-
ines are needed that can be more rapidly produced and can
vercome challenges such as immunosenescence, annual
evaccination, and lower protection against drifted viruses.
deally, better vaccines would stimulate longer-lasting cross-
eactive immunity against multiple strains.
Vaccines must be effective in protecting the very young,
he chronically ill, and the elderly, who bear the largest
urden of inﬂuenza illness. Also needed is a better under-
tanding of how to motivate people to seek annual inﬂuenza
accination.
oi:10.1016/j.ijid.2010.02.1507
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vercoming limitations of seasonal vaccines
.S. Monto
University of Michigan School of Public Health, Ann Arbor,
I, USA
Among the limitations of seasonal inﬂuenza vaccines are
imited breadth of immunity, short duration of protection,
ower protection in older individuals and immunocompro-
ised patients, problems with needle inoculation such as
eedle phobia and medical waste disposal, and dependence
n the egg supply. Because antigenic drift (poor antigenic
atch between the vaccine and circulating strains) is asso-
iated with a fall in efﬁcacy, there is a need for vaccines
hat will induce an immune response to both identical and
elated strains. In an effort to produce broadened immunity,
ew adjuvanted vaccines with different oil components have
een formulated, and the concept of a universal inﬂuenza
accine continues to be explored. It is not clear whether
roducing a higher titer postvaccination will result in longer
uration of protection, as that requires speciﬁc evaluation
nvolving major practical difﬁculties. Improved technology
or inﬂuenza vaccines may result in vaccines intended for
peciﬁc population segments, such as younger children and
he elderly. A quadrivalent vaccine may be developed con-
aining the two A subtypes and the two B lineages, which
ould be most useful in children. To combat the issue of
mmunosenescence, a high-dose vaccine has recently been
pproved for use in older patients. Some studies suggest that
nvaccinated older individuals may be more ill but because
f their disability, underutilize the healthcare system; in
ontrast, vaccinated older individuals may be healthier
ecause they are in care, indicating bias in analyses. It may
e possible that these new vaccines will produce protec-
ion in the immunocompromised, but this will need to be
valuated speciﬁcally. To address problems associated with
eedle inoculation, new delivery systems and alternative
outes to intramuscular administration have been devel-
ped, such as a nasal vaccine approved in the United States
n 2007 and an intradermal vaccine approved recently in
urope. Cell culture production of inﬂuenza vaccines may
mprove vaccine efﬁcacy and would reduce the system’s
trac
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dependence on the egg supply and provide greater produc-
tion ﬂexibility.
doi:10.1016/j.ijid.2010.02.1508
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Emerging Trends: Vaccines in late development
R.L. Atmar
Baylor College of Medicine, Houston, TX, USA
A number of strategies are being pursued to increase the
availability of and to improve the immunogenicity, efﬁcacy,
and effectiveness of seasonal inﬂuenza vaccines. Many of
these approaches have led to vaccine candidates that are
in the late stages of clinical evaluation (i.e., Phase 3 trials)
or that have been recently licensed. Approaches to increase
the availability of inﬂuenza vaccines in the United States
include the licensure of vaccines approved in other countries
and the production of inﬂuenza virus antigens by cell cul-
ture (eg, canine kidney cells and Vero cells) rather than by
growth in embryonated eggs. Some cell culture-derived vac-
cines are approved in Europe. The inﬂuenza hemagglutinin is
partially puriﬁed from whole virus in currently licensed vac-
cines. Another approach is the production of inﬂuenza virus
hemagglutinin with a baculovirus expression system. Alter-
native routes of immunization have also been explored, and
an intradermally administered vaccine has recently been
approved for use in persons 60 years of age and older in
Europe. Improved vaccine immunogenicity and efﬁcacy may
be attained through the use of adjuvants or higher doses
of hemagglutinin. Although several adjuvanted inﬂuenza
virus vaccines are approved in other countries, none are
licensed in the United States. However, oil-in-water adju-
vants are in advanced stages of evaluation. A high-dose (60
mcg hemagglutinin) trivalent inﬂuenza vaccine has recently
been licensed based upon its superior immunogenicity com-
pared with the standard dose (15 mcg hemagglutinin), to be
used in persons 65 years of age and older. Phase 4 studies of
the high-dose vaccine are under way to determine whether
the improved immunogenicity is associated with increased
vaccine efﬁcacy and effectiveness.
doi:10.1016/j.ijid.2010.02.1509
Traveler’s diarrhea and enteric diseases of Latin
America (Invited Presentation)
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Epidemiology of Traveler’s Diarrhea
A. McCarthy
Ottawa Hospital, Ottawa, ON, Canada
This presentation will provide a review of etiologies and
risk factors for diarrhea in those visiting Latin America and
will provide some comparison with travelers to other desti-
nations.
doi:10.1016/j.ijid.2010.02.1510
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raveler’s Diarrhea: Prevention and Treatment
. Steffen
University of Zurich, Zurich, Switzerland
Different options for the prevention of travelers’ diarrhea
TD) exist. Risk reduction is possible by implementing the
azard Analysis Critical Control Point System or by improve-
ent of the local infrastructure. To abandon travel plans
r to abstain from potentially contaminated food and bev-
rages is not attractive. Both a cholera and a candidate
T-ETEC transcutaneous patch vaccine have been shown to
revent TD by LT-ETEC strains, possibly by other pathogens.
mong drugs suggested for chemoprophylaxis, probiotics
howed at best a low protective efﬁcacy rate; bismuth sub-
alicylate was modestly effective. Many older antibacterial
gents are obsolete because of antimicrobial resistance by
revalent enteric bacterial pathogens. The fear of systemic
eactions has limited the prescription of ﬂuoroquinolones.
oorly absorbed antibiotics, mainly rifaximin, are more
ttractive for compliant travelers.
As no current prophylactic measure is satisfactory, (self)-
herapy of TD remains an important option (travel kit!). Only
ew still recommend to wait for spontaneous cure; rapid
elief is often important as incapacitation and the necessity
o change travel plans have a great impact. Probiotics and
harcoal have been demonstrated to offer no clinically rel-
vant beneﬁt. Oral rehydration solutions have no effect on
he duration or amount of diarrhea, but they are essential in
aediatric patients and senior travelers. Antimotility agents
ffer fast relief, but they are contraindicated in dysentery,
lso they are often followed by a period of constipation.
Antimicrobial agents, mainly quinolones and particularly
n SE-Asia also azithromycin, have been used in this decade,
lthough there is only limited recent data on the frequency
f resistance from analysis of TD stool samples on all con-
inents. The non-absorbed rifamycin-derivative rifaximin —
ith a broad antimicrobial spectrum and a tolerance pro-
le similar to placebo — has been demonstrated in patients
ith TD to be as effective as ciproﬂoxacine, but this only in
on-invasive cases of TD.
oi:10.1016/j.ijid.2010.02.1511
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elminths of Latin America
. Coyle
Albert Einstein College of Medicine, Bronx, NY, USA
This session will focus on intestinal helminths. Ascaris
umbricoides is among the most prevalent of parasitic
nfections in humans. Most patients are asymptomatic or
xperience mild abdominal pain. Children have the high-
st intensity of infections and generally present with more
evere clinical manifestations. The most common clinical
yndromes of ascariasis are pneumonitis, intestinal, bil-
ary and pancreatic obstruction. Ascariasis adversely affects
rowth, development, and nutritional status of children.
nother helminth, Hookworm, is particularly troubling for
hildren and women of reproductive age who are vulnerable
